Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: Assessment with serum type I collagen breakdown products

Bone

Volumn 24, Issue 4, 1999, Pages 381-385

  Garnero, P ^a   Jouvenne, P ^a   Buchs, N ^a   Delmas, P D ^a   Miossec, P ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone markers; Osteocalcin; Pyridinoline; Rheumatoid arthritis; Type I collagen cross links

Indexed keywords

COLLAGEN TYPE 1; METHOTREXATE; OSTEOCALCIN; PREDNISONE; PYRIDINOLINE;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; JOINT DESTRUCTION; MALE; OSSIFICATION; OSTEOLYSIS; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; EVALUATION STUDIES; FEMALE; HUMANS; JOINT DISEASES; MALE; METHOTREXATE; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; STEROIDS;

EID: 0033120581     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00193-8     Document Type: Article

References (40)

1. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.E., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
2. Astbury C., Bird H.A., McLaren A.M., Robins S.P. Urinary excretion of pyridinium collagen crosslinks correlates with joint damage in arthritis. Br J Rheumatol. 33:1994;11-15.
3. Bertlini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tissue necrosis factors. Nature. 319:1986;516-518.
4. Black D., Marabani M., Sturrock R.D., Robins S.P. Urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Ann Rheum Dis. 48:1989;641-644.
5. Blumsohn A., Herrington K., Hannon R.A., Shao P., Eyre D.R., Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 79:1994;730-735.
6. Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P.D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an eight amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 12:1997;1028-1034.
7. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 40:1994;2022-2025.
8. Christgau S., Alexendersen P., Schlemmer A., Bonde M., Christiansen C. Biological variation of the serum concentration of degradation products derived from the C-terminal telopeptide of type I collagen measured by a new version of the CrossLaps ELISA. J Bone Miner Res. 12:(Suppl.):1997;S497.
9. Compston J.E., Vedi S., Croucher P.I., Garrahan N.J., O'Sullivan M.M. Bone turnover in non-steroid treated rheumatoid arthritis. Ann Rheum Dis. 53:1994;163-166.
10. Eyre D.R. Collagen crosslinking amino-acids. Meth Enzymol. 144:1987;115-139.
11. Garnero P., Delmas P.D. Bone markers. Woolf A.D., Balliere's Clinical Rheumatology. Vol. 11:1997;517-537 Ballière Tindall, London.
12. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 7:1992;1389-1398.
13. Garnero P., Grimaux M., Seguin P., Delmas P.D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 9:1994;255-264.
14. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 11:1996;337-349.
15. Gough A.K.S., Lilley J., Eyre S., Holder R.L., Emery P. Generalized bone loss in patients with rheumatoid arthritis. Lancet. 344:1994;23-27.
16. Gough A.K.S., Peel N.F.A., Eastell R., Holder R.L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis. 53:1994;14-17.
17. Hakala M., Aman S., Luukkainen R., Risteli L., Kauppi M., Nieminen P., Risteli J. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis. 54:1995;886-890.
18. Hall G.M., Spector T.D., Delmas P.D. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum. 38:1995;902-906.
19. Hall G.M., Spector T.D., Griffin A.J., Jawad A.S.M., Hall M.L., Doyle D.V. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 36:1993;1510-1516.
20. Hanson D.A., Weiss M.A.E., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption Quantitation of type I collagen cross-linked N-telopeptides in urine . J Bone Miner Res. 7:1992;1251-1258.
21. Hassager C., Jensen L.T., Podenphant J., Thomsen K., Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption The effect of Nandrolone decanoate and hormone replacement therapy . Calcif Tissue Int. 54:1994;30-33.
22. Hein G., Franke S., Müller A., Bränig E., Eidner T., Stein G. The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis. Clin Rheumatol. 16:1997;167-172.
23. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Eng J Med. 333:1995;142-146.
24. Kollerup G., Hansen M., Horsley-Petersen K. Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis Relation to disease activity and effects of methyl-prednisolone . Br J Rheumatol. 33:1994;816-820.
25. Kotaniemi A., Isomaki Hakala M., Risteli L., Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol. 21:1994;1593-1596.
26. Kroger H., Arnala I., Alhava E.M. Bone remodeling in osteoporosis associated with rheumatoid arthritis. Calcif Tissue Int. 49:(Suppl.):1991;S90.
27. Larsen A., Dale K., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. 18:1977;481-491.
28. Lems W.F., Gerrits M.I., Jacobs J.W.J., van Vugt R.M., van Rijn H.J.M., Bijlsma J.W.J. Changes in markers of bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 55:1996;288-293.
29. Lems W.F., Jacobs J.W.G., Van den Brink H.R., Van Rijn H.J.M., Bijlsma J.W.J. Transient decrease in osteocalcin and markers of type I collagen turnover during high dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol. 32:1993;787-789.
30. Lips P., van Ginkel F.C., Netelenbos C., Wiersinga A., van den Vigh W.J.F. Lower mobility and markers of bone resorption in the elderly. Bone Miner. 9:1990;49-57.
31. Mellish R.W.E., O'Sullivan M.M., Garrahan N.J., Compston J.E. Iliac crest trabecular bone mass and structure in patients with non-steroid rheumatoid arthritis. Ann Rheum Dis. 46:1987;830-836.
32. Mundy G.R., Boyce B.F., Yoneda T., Bonewald L.F., Roodman G.D. Cytokines and bone remodeling. Marcus R., Feldman D., Kesley J., Osteoporosis. 1996;301-313 Academic, San Diego, CA.
33. Nygen L., Dewhirst F.E., Hauschka P.V., Stashenko P. Interleukin 1β stimulates bone resorption and inhibits bone formation in vivo. Lympho Cytok Res. 10:1991;15-19.
34. Ristelli J., Elomaa I., Niemi S., Novamo A., Ristelli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen A new serum marker of bone collagen degradation . Clin Chem. 39:1993;635-640.
35. Ritchie D.M., Boyle J.A., McInnes J.M., Jasani M.K., Dalakos T.G., Grieveson P., et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 37:1968;393-406.
36. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 9:1994;1643-1649.
37. Schlemmer A., Hassager C., Jensen S.B., Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab. 74:1992;476-480.
38. Seyedin S., Zuk R., Kung V., Daniloff Y., Shepard K. An immunoassay to urinary pyridinoline The new marker of bone resorption . J Bone Miner Res. 8:1993;635-642.
39. Spector T.D., James I.T., Hall G.M., Thompson P.W., Perrett D., Hart D.J. Increased levels of urinary collagen cross links in females with rheumatoid arthritis. Clin Rheumatol. 12:1993;240-244.
40. Steinbrocker O., Traeger C.H., Batterman R.C. Therapeutic criteria in rheumatoid arthritis. JAMA. 140:1949;659-662.